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“The whole of science is nothing more than a refinement of everyday thinking.” 
(Albert Einstein)
Pulmonary arterial hypertension (PAH) is a rare but deadly cardiopulmonary disease, which 
has an unclear and multifactorial pathobiology [1]. Unfortunately, despite availability of 13 
Food and Drug Administration-approved therapeutic interventions, the 5-year survival rate is 
just 21–64% [2]. An important clinical need exists to better understand the molecular 
mechanisms that lead to PAH development. In addition, a growing interest exists in the use 
of personalised medicine approaches for PAH, since such a strategy is meritorious in other 
proliferative diseases, such as cancer [3, 4].
PAH is characterised by dysregulated vasoconstriction, muscularisation of small pulmonary 
arteries, and formation of obstructive plexiform lesions [5]. The exact initiating event(s) and 
early mechanisms driving PAH progression remain inconclusive and are an area of intense 
research interest. Unlike the field of cancer, efforts to address these questions in PAH have 
historically been hindered by lack of access to patient samples. In contrast to other 
pulmonary diseases, such as interstitial lung disease, inflammatory lung disease, lung cancer 
or acute lung injury states, lymph node biopsies, parenchymal biopsies or bronchoalveolar 
lavage are contraindicated or not useful in PAH [6]. Efforts focused on patient specimens 
therefore have centred on explanted lungs at the time of lung transplantation or on studying 
circulating cells such as peripheral blood mononuclear cells (PBMCs) or blood outgrowth 
endothelial cells (BOECs). However, isolating cells and tissues from explanted lungs limits 
access to those patients with end-stage PAH. In addition, lung transplantation for PAH is 
infrequently performed [7]. PBMCs and BOECs, furthermore, are limited by their unclear 
relationship with the events in the pulmonary vasculature (PBMCs, BOECs), their unclear 
origin (BOECs) and the need to obtain large blood volumes (BOECs) [8–11]. There is an 
unmet need for human pulmonary vascular cells isolated from living patients and at early 
stages of PAH to examine changes in cell function during disease progression and in 
response to therapies.
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While the initiating pulmonary vascular injury is multifactorial and incompletely understood 
(likely a perfect storm of genetic and environmental factors), the integral contribution of 
pulmonary artery endothelial cells (PAECs), one of the major cell types comprising the 
pulmonary vasculature, to PAH pathology is evident. Two main theories describe how 
dysfunctional PAECs directly or indirectly contribute to disease progression. The first line of 
evidence posits that the endothelium exhibits disordered proliferation and angiogenic 
responses after pulmonary vascular injury [5]. Analysis of human PAH lung tissue suggests 
that the imbalance of these processes leads to formation of obliterative plexiform lesions (a 
hallmark of advanced PAH). Building on this finding, later evidence indicated that PAECs in 
plexiform lesions are of monoclonal origin (likely driven by somatic mutations in growth 
regulatory genes) [12] and that PAH PAECs exhibit chromosomal abnormalities that confer 
a growth advantage [13]. These changes are associated with apoptosis resistance [14]. A 
second theory posits that pulmonary vascular rarefaction observed in PAH is being driven by 
PAH PAEC-mediated accelerated and sustained apoptosis, rather than apoptosis resistance 
[15]. Importantly, dysfunctional PAECs spur on disease progression not only by mis-
regulating the balance between growth and apoptosis, but also by affecting their 
microenvironment and the cells surrounding them. PAH PAECs accomplish this by releasing 
an abnormal secretome, inducing pulmonary artery smooth muscle cell hyperproliferation, 
fibroblast activation and immune cell recruitment, providing a disease-promoting feedback 
loop and culminating in pulmonary vascular dropout and formation of plexiform lesions [5, 
16]. PAH PAECs clearly are an integral driver of PAH pathogenesis, but several critical 
questions remain: How does PAEC dysfunction progress during the course of PAH? Does 
PAEC apoptosis occur before PAEC apoptosis resistance arises? Is PAEC hyperproliferation 
a feature of all PAH patients or is this limited to specific patient subtypes and disease stages? 
What metabolic or epigenetic changes do PAH PAECs undergo? Which mechanisms drive 
early PAH progression? How do therapeutics affect the function of PAH PAECs?
In this issue of the European Respiratory Journal, VENTETUOLO et al. [17] demonstrate 
feasibility of a technique that may begin to address these questions. A reproducible method 
to harvest viable PAECs from living PAH patients has been an ongoing objective in the field. 
While a ground-breaking method of isolating PAECs from the balloon at the tip of the 
pulmonary artery catheter (PAC) was first published several years ago by POLLET et al. 
[18], this method has not widely been adapted due to technical and logistical challenges. 
VENTETUOLO et al. [17] built upon the work by POLLET et al. [18] and have developed a 
modified method for PAC-based PAEC isolation. The authors provide detailed, transparent 
procedural level details of their method and share what they have learned along the way. Of 
note, some details of the protocol differ from those published in the prior report (e.g. lack of 
trypsinisation, centrifugation, lysis, cell sorting), suggesting that PAC-based PAEC isolation 
is a “tricky business” and that protocols working at one institution may not be successful at 
another. The authors are to be commended for the level of detail they provide, which will 
certainly make it easier for investigators at other institutions to implement this technique. 
Aside from providing a detailed protocol, this report has several other strengths: first, the 
authors include a large variety of pulmonary hypertension (PH) phenotypes (not just PAH), 
thus mimicking a real-world scenario, where many PH referrals have non-PAH PH. Second, 
in some patients, several isolation attempts occurred throughout their disease course, thus 
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providing details on the feasibility of serial PAEC assessments. Third, the authors provide 
the first evidence that it may be feasible to link PAEC function assessed ex vivo/in vitro with 
clinical parameters or disease type. Since right heart catheterisation is a fundamental 
diagnostic technique that often is repeated throughout a PAH (or even PH) patient’s disease 
progression, it could allow for collecting PAECs across repetitive samples at various disease 
stages.
Several findings of this study are notable: First, the authors successfully cultured PAECs 
from 19 of 49 PAC balloon tips, establishing a success rate of 39%. Second, the investigators 
identified a positive correlation between successful PAEC culture and cardiac index and 
pulmonary vascular resistance, suggesting that more profound haemodynamic alterations are 
associated with a higher rate of successful PAEC isolation and culture. Third, the authors 
demonstrate that functional assays (investigating apoptosis, migration and tube formation) 
are feasible in isolated PAH PAECs and may provide clinically relevant phenotypic 
information. Interestingly, the patient-derived PAEC lines demonstrated substantial 
variability in terms of growth and functional assays. Whether this variability indeed is due to 
true biological differences between patients or due to technical factors remains to be 
determined. If there indeed are robust phenotypical differences between cells from different 
patients, PAEC ex vivo characterisation would represent a powerful new tool for diagnosis 
and patient phenotyping and possibly also for risk stratification and treatment selection, thus 
representing a significant step towards a personalised medicine approach. With the rise of 
the -omics area, there is also a tremendous potential for using such approaches on isolated 
PAH (or PH) PAECs. An exciting prospect is that PAH medications could be selected based 
on cellular characteristics, and that treatment responses could be evaluated directly and in 
real time. Such an ex vivo drug response assessment may even be helpful for non-PAH 
forms of PH, where selected patient populations may still be responsive to treatment with 
PAH-specific drugs [19, 20]. In contrast to cells harvested from lung explants, such ex vivo 
interrogations would even be feasible in at-risk populations and early disease stages, and 
could also be repeated over time. In the current manuscript, PAEC culture from serial 
catheterisations was met with success in one patient.
Despite this step forward, several questions remain. This study did not attempt to link 
disease severity or subtype to PAEC function and was underpowered to do so. This will be 
valuable for future investigations, not only for PAH but also other groups of PH, several of 
which do not have viable therapeutic interventions or biobanked tissue samples. 
Furthermore, PAECs from PAC balloon tips by default are isolated from proximal 
pulmonary arteries. PAH, on the other hand, is a disease of distal vessels, raising the 
question of how relevant proximal PAECs are to disease development and progression. 
However, it has now been established that changes in the mechanical properties of the 
proximal pulmonary artery contribute to right ventricle dysfunction and distal pulmonary 
artery remodelling [21], possibly implying proximal PAECs as disease modifier. Studies of 
these cells may therefore identify new mechanisms and pathways driving PAH. However, at 
least some of the cultured cells could have been derived from central veins, the right heart, 
or circulating blood derived cells. While the authors performed preliminary studies to 
minimise this possibility, further investigations are needed to eliminate this scenario for sure. 
As omics-based approaches become more refined at detecting different cell populations 
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within a single cell type, we may be able to discern differences between PAECs originating 
from different locations. Finally, the rate of successful isolation and culture was only 39%. 
Since PAEC isolation and culture are labour- and time-intensive, significant resources are 
needed and would be “wasted” in >50% of cases. Since successful culture was associated 
with more pronounced haemodynamic alterations, evaluation of earlier and milder disease 
stages could be challenging. Additional experience with the technique and technological 
advances will hopefully increase the yield.
Ultimately, studies of a larger sample size and reproducibility of the protocol by other 
scientists are needed. However, the work by VENTETUOLO et al. [17] is a significant step 
in answering if/how PAEC changes affect PAH pathogenesis and if they can be used for ex 
vivo diagnostics and drug testing, suggesting a huge potential for significant progress in the 
field.
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